Blaine Hobson
Chair of Investment Committee @ Whitecap Venture Partners
Toronto, Canada
Blaine Hobson is a seed investor at Whitecap Venture Partners in Toronto focused on Analytics and Health Care. Blaine Hobson is based out of Toronto, Ontario and is the Chair of Investment Committee of Whitecap Venture Partners. Blaine previously worked at Avo Photonics as a Chief Executive Officer. Blaine Hobson attended the Ivey School of Business.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries Blaine Hobson invests in
Stages Blaine Hobson invests in
Countries Blaine Hobson invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Analytics 1 (11%)
- Health Care 1 (11%)
- Biotechnology 1 (11%)
- Medical Device 1 (11%)
- Service Industry 1 (11%)
Stage
- Seed 2 (22%)
- Series A 1 (11%)
- Series B 1 (11%)
- Funding Round 1 (11%)
- Venture - Series Unknown 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Qvella Corporation
|
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable resultsin clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples. | Venture - Series Unknown / Sep 08, 2021 | |
|
Qvella Corporation
|
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable resultsin clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples. | Venture - Series Unknown / Aug 12, 2020 | |
|
Qvella Corporation
|
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable resultsin clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples. | Venture - Series Unknown / Mar 31, 2019 | |
|
Qvella Corporation
|
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable resultsin clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples. | $20M / Series B / Dec 04, 2017 | |
Real Matters
|
Real Matters is the leading provider of property information services in North America. It fuses unique data gathered from a network of more than 17,000+ field agents with the technological power of its cloud-based redihiveTM environment to propel the next generation of businesses that provide insight into residential and commercial properties. Theorganization has its Canadian head office in Toronto Ontario as well as a U.S. office in Chicago. | $73.1M / Mar 02, 2016 | |
|
Qvella Corporation
|
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable resultsin clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples. | $20M / Series A / Oct 29, 2015 | |
|
Real Matters
|
Real Matters is the leading provider of property information services in North America. It fuses unique data gathered from a network of more than 17,000+ field agents with the technological power of its cloud-based redihiveTM environment to propel the next generation of businesses that provide insight into residential and commercial properties. Theorganization has its Canadian head office in Toronto Ontario as well as a U.S. office in Chicago. | $60M / May 04, 2015 | |
|
Qvella Corporation
|
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable resultsin clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples. | $2.4M / Seed / Mar 01, 2015 | |
|
Real Matters
|
Real Matters is the leading provider of property information services in North America. It fuses unique data gathered from a network of more than 17,000+ field agents with the technological power of its cloud-based redihiveTM environment to propel the next generation of businesses that provide insight into residential and commercial properties. Theorganization has its Canadian head office in Toronto Ontario as well as a U.S. office in Chicago. | Seed / Jan 01, 2007 |
Co-Investors
Whitecap Venture Partners is a Canadian-based Venture Capital fund investing in early stage technology companies. Whitecap is headquartered in Toronto and invests across Canada and the Northeastern US. Since Whitecap’s inception the early 1990s, Whitecap recognises the power of real collaboration between entrepreneurs and investors. This rapportenables them to provide significant value to companies along with strong returns across investment cycles.Whitecap specialises in Information & Communication Technologies (ICT) and Medical Technologies. Whitecap is continually searching for upcoming ventures to support as the next generation of exceptional enterprises.
Whitecap Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Blaine Hobson
Chair of Investment Committee
|
|||
Carey Diamond
Managing Director/Co-founder
|
|||
Damien Steel
Venture Partner
|
|||
Kim Coote
VP of Finance
|
|||
Natalie Smith
Senior Analyst
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Blaine Hobson invest in?
Blaine Hobson invests primarily in Analytics, Health Care and Biotechnology startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Blaine Hobson?
Public channels for Blaine Hobson include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Blaine Hobson last invest?
The most recent investment recorded for Blaine Hobson closed in Sep 2021. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
